SEC Filings - MiNK Therapeutics

Form	Description	Filing date	View
5	Annual filing director officer or owner of more than ten percent.	Feb 14, 2022	View HTML 0000899243-22-006140.pdf 0000899243-22-006140.rtf 0000899243-22-006140.xls
10-K	Annual report which provides a comprehensive overview of the company for the past year	Mar 18, 2022	View HTML 0001564590-22-011026.pdf 0001564590-22-011026.rtf 0001564590-22-011026.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
10-K	Annual report which provides a comprehensive overview of the company for the past year	Mar 24, 2023	View HTML 0000950170-23-009762.pdf 0000950170-23-009762.rtf 0000950170-23-009762.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
10-K	Annual report which provides a comprehensive overview of the company for the past year	Mar 21, 2024	View HTML 0000950170-24-034672.pdf 0000950170-24-034672.rtf 0000950170-24-034672.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
CORRESP	CORRESP	Oct 12, 2021	View HTML 0001193125-21-296966.pdf 0001193125-21-296966.rtf 0001193125-21-296966.xls
CORRESP	CORRESP	Oct 12, 2021	View HTML 0001193125-21-296972.pdf 0001193125-21-296972.rtf 0001193125-21-296972.xls
CORRESP	CORRESP	Sep 13, 2021	View HTML 0001193125-21-271924.pdf 0001193125-21-271924.rtf 0001193125-21-271924.xls
CORRESP	CORRESP	Sep 24, 2021	View HTML 0001193125-21-282464.pdf 0001193125-21-282464.rtf 0001193125-21-282464.xls
CORRESP	CORRESP	Nov 07, 2022	View HTML 0001193125-22-278982.pdf 0001193125-22-278982.rtf 0001193125-22-278982.xls
DRS	Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy	Jan 22, 2021	View HTML 0000950123-21-000524.pdf 0000950123-21-000524.rtf 0000950123-21-000524.xls

Data provided by Kaleidoscope.